Novartis is stepping on the cGAS. Three years after securing an option on an IFM Therapeutics subsidiary, the Swiss drugmaker has accelerated into the deal and paid $90 million upfront for small ...
Just five months after Novartis put down $310 million for IFM Therapeutics’ inflammation-focused unit, the Big Pharma has come back for more. This time, it is teaming up with IFM Due, the subsidiary ...
Industry super’s IFM Investors has strangled tollroads investor Atlas Arteria with its kitbag of raids, creeps and boardroom games, so it may as well finish the job. The only problem is its intent on ...
Capital Brief on MSN
Atlas Arteria shares jump 12.5% following IFM takeover bid
More news: Atlas Arteria shares surged 12.47% by 10.39am (AEST) after resuming trading following a pause as it updated the ...
Milestone marks the third major acquisition for an IFM Therapeutics subsidiary in the past seven years The acquisition provides Novartis with full rights to IFM Due's portfolio of STING antagonists, ...
The deal is expected to close in the first quarter of this year Marathon Capital acted as financial advisor to GreenGas on the transaction IFM Investors has $143 billion under management as of ...
TORONTO, Dec. 9, 2025 /CNW/ - IFM Investors today announced the opening of a Toronto office, marking a significant milestone in the firm's expanding global footprint and reinforcing its long-term ...
IFM Therapeutics LLC, an innate immunity specialist that's quickly sparked major deals with big pharma, is stoking the generative fire at its heart with $55.5 million in new financing led by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results